Alnylam Pharmaceuticals Inc. has appointed Pushkal Garg, M.D., as Executive Vice President and Chief Research and Development Officer to lead an integrated R&D organization. This organizational change aims to enhance pipeline progress and facilitate faster decision-making as the company enters a new phase of growth. Alnylam is focused on delivering RNAi therapeutics to all major tissues by 2030, building on its recent launch of AMVUTTRA® for transthyretin amyloidosis with cardiomyopathy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.